In an otherwise healthy adult male with recent onset Peyronie's disease, is oral vitamin E an effective treatment?

Vitamin E for Peyronie's Disease Treatment

Oral vitamin E is not recommended for the treatment of Peyronie's disease due to lack of proven efficacy and should be avoided as it may delay more effective interventions. 1

Guideline-Based Recommendations

The most recent 2025 European Association of Urology guidelines explicitly state that oral vitamin E is not recommended for Peyronie's disease treatment due to lack of proven efficacy, and its use may delay more effective interventions. 1 This represents the strongest current evidence against vitamin E use.

The 2015 American Urological Association guidelines similarly recommend that clinicians should not offer oral therapy with vitamin E (Moderate Recommendation; Evidence Strength Grade B). 2 The AUA panel determined that using therapies without proven efficacy constitutes a moderate risk/burden by:

• Postponing or pre-empting more efficacious treatments 2
• Failing to alleviate patient distress 2
• Wasting time on ineffective treatments 2
• Incurring unnecessary costs 2

Evidence from Clinical Trials

The highest quality randomized controlled trial showed no benefit. A 2007 double-blind, placebo-controlled study of 236 men with Peyronie's disease found that vitamin E (300 mg twice daily for 6 months) showed no statistically significant improvement compared to placebo in:

• Pain reduction (60.4% vs 59.2% placebo, p=0.1) 3
• Penile curvature (18.9% vs 18.4% placebo, p=0.09) 3
• Plaque size (11.3% vs 11.1% placebo, p=0.1) 3

Combination therapy with vitamin E also failed. The same study evaluated vitamin E combined with propionyl-L-carnitine and found no significant benefit over placebo for any measured outcome. 3

Vitamin E combined with interferon showed no advantage. A 2006 randomized prospective study found that intralesional interferon-alpha 2b combined with oral vitamin E (400 IU twice daily for 6 months) did not produce statistically significant changes in objective or subjective parameters compared to vitamin E alone or interferon alone. 4

Conflicting Lower-Quality Evidence

One 2013 study (70 patients) suggested vitamin E as part of multimodal therapy showed plaque size reduction of -50.2% versus -35.8% in controls (p=0.027). 5 However, this study used vitamin E combined with verapamil injections, iontophoresis, blueberries, propolis, and topical diclofenac, making it impossible to attribute benefit specifically to vitamin E. 5 This study should not change practice given the clear guideline recommendations and higher-quality negative trials.

Network Meta-Analysis Findings

A 2024 Bayesian network meta-analysis of 24 studies (1,643 participants) found no statistically significant treatment effect for vitamin E compared to placebo for curvature degree, plaque size, or erectile function. 6 While frequentist analysis suggested some benefit for vitamin E 300 mg in curvature and plaque size, the Bayesian approach (which better accounts for uncertainty) showed no significant effect. 6

What to Offer Instead

For active disease with pain:

• NSAIDs for pain management 1
• Daily tadalafil 5 mg (demonstrated lower curvature progression rates) 1

For stable disease with curvature:

• Intralesional collagenase clostridium histolyticum (FDA-approved, mean 17° reduction vs 9.3° placebo) 2
• Penile traction therapy (safe, though requires 2-8 hours daily use) 1
• Surgical options for stable disease >3-6 months 1

Clinical Pitfalls

Do not prescribe vitamin E simply because patients request it or because it seems "harmless." 2 Even without significant adverse effects, prescribing ineffective therapy:

• Delays definitive treatment during the critical window when disease may be more responsive 2
• Creates false hope and prolongs patient distress 2
• Wastes healthcare resources 2

Be aware that 21% of urologists still prescribe vitamin E despite guideline recommendations against it. 7 This represents non-evidence-based practice that should be avoided. 7